Llwytho...
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
Despite the improvement in clinical outcomes derived by the introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours harbour EGFR-activating mutations, prognosis remains...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | ESMO Open |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BMJ Publishing Group
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5070275/ https://ncbi.nlm.nih.gov/pubmed/27843613 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2016-000060 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|